GlassScriptPhysician profile
Nina Singh
NPI 1881850261
$8,135.46
in general payments reported to CMS, 2019-2025
36 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $679 · 2021: $1,050 · 2022: $935 · 2023: $1,144 · 2024: $1,625 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.81 |
| Education | $108.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,651.43 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,070.98 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,042.07 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $562.80 | 2019-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $411.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $302.09 | 2023-2025 | |
| Celltrion USA INC. | $278.16 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Celgene Corporation | $263.87 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $238.53 | 2020-2025 | Tremfya |
| Boston Scientific Corporation | $228.32 | 2021-2025 | Exalt Model D, Compliance Endokit, General - Hemostasis |
| Ardelyx, INC. | $219.78 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $217.83 | 2024-2025 | Omvoh |
| Pfizer INC. | $185.80 | 2023-2025 | |
| Medtronic, INC. | $170.81 | 2022 | |
| Intercept Pharmaceuticals, INC. | $170.15 | 2019-2025 | Ocaliva |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $143.55 | 2020-2024 | Dificid |
| Qol Medical, LLC | $130.74 | 2023-2024 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $120.31 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $114.04 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $83.27 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $78.73 | 2023-2024 | Dupixent |
| Allergan, INC. | $65.80 | 2019-2020 | |
| Novo Nordisk INC | $63.89 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $42.92 | 2020-2025 | Injectafer |
| Endo Pharmaceuticals INC. | $40.55 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.47 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $32.73 | 2025 | Terlivaz |
| Amgen INC. | $25.97 | 2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $25.71 | 2019-2021 | |
| Micro-Tech Endoscopy USA, INC. | $19.14 | 2021 | |
| Organon LLC | $18.22 | 2023 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $17.66 | 2023 | Idacio |
| Aurinia Pharma U.S., INC. | $17.05 | 2025 | Lupkynis |
| Redhill Biopharma INC. | $16.32 | 2022 | |
| Lumendi LLC | $14.90 | 2021 | |
| Vivus LLC | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.